An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency

References

• Buist S, Burrows B, Cohen A, et al. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. Am Rev Respir Dis. 1989;140(5):1494–1497. doi:10.1164/ajrccm/140.5.14942683912
   PubMed Web of Science ®Google Scholar
• Stoller JK, Snider G, Brantly M, et al. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900. doi:10.1164/rccm.168.7.81814522813
   PubMed Web of Science ®Google Scholar
• Abboud RT, Ford GT, Chapman KR, et al. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J. 2001;8(2):81–88. doi:10.1155/2001/82427311320399
   PubMedGoogle Scholar
• Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19(2):109–116. doi:10.1155/2012/92091822536580
   PubMed Web of Science ®Google Scholar
• Brantly M, Campbell E, Carrell R, et al. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397–415.9447774
   PubMed Web of Science ®Google Scholar
• Vidal R, Blanco I, Casas F, et al. Guidelines for the diagnosis and management of α1-antitrypsin deficiency (English Version). Arch Bronconeumol. 2006;42(12):645–659.17178069
   PubMed Web of Science ®Google Scholar
• de la Roza C, Lara B, Vilá S, Miravitlles M. α1-antitrypsin deficiency: situation in spain and development of a screening program (english version). Arch Bronconeumol. 2006;42(6):290–298.16827978
   PubMed Web of Science ®Google Scholar
• Boie J, Corhay J-L, Derom E, et al. Belgian guidelines for diagnosis and management of patients with α1-antitrypsin deficiency. Belgian Thoracic Society’s α1-Antitrypsin Deficiency Working Party. 2009;1–15. Available from: https://www.bvp-sbp.org/files/Guidelines_Alfa_1_antitrypsine_deficientie_dec_2009.pdf. Accessed 33, 2019.
   Google Scholar
• Fjellner C, Schlyter C, Baker M, et al. Alpha-1 in the European Union expert recommendations: recommendations of the alpha-1 expert group initiated and chaired by members of the European parliament. 2012; 1–16. Available from: https://www.ft.dk/samling/20151/almdel/SUU/bilag/480/1613994.pdf. Accessed 33, 2019.
   Google Scholar
• Menga AG, Miravitlles M, Blanco I, et al. Guidelines on Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency. Argentina Assoc Respir Med Ramr. 2014;14(1):1–14.
   Google Scholar
• Hutsebaut J, Janssens W, Louis R, et al. Activity of the alpha-1 antitrypsin deficiency registry in Belgium. J Chronic Obstr Pulm Dis. 2015;12(1):10–14. doi:10.3109/15412555.2015.1021916
   Web of Science ®Google Scholar
• Casas F, Blanco I, Martínez MT, et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. Arch Bronconeumol. 2015;51(4):185–192. doi:10.1016/j.arbres.2014.05.00825027067
   PubMed Web of Science ®Google Scholar
• Chorostowska-Wynimko J, Bakuła A, Kulus M, et al. Standards for diagnosis and care of patients with inherited alpha-1 antitrypsin deficiency recommendations of the polish respiratory society, polish society of pediatric pulmonology and polish society of pediatric gastroenterology. Pneumonol Alergol Pol. 2016;84(3):193–202. doi:10.5603/PiAP.2016.002327238183
   PubMedGoogle Scholar
• Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J. 2017;50(5). doi:10.1183/13993003.00711-2017
   Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Brantly ML, et al. Journal of the COPD foundation clinical practice guidelines: the diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668–682. doi:10.15326/jcopdf.3.3.2015.018228848891
   PubMed Web of Science ®Google Scholar
• Ford GT, Abboud RT, Guenter CA. Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. ad hoc committee on alpha-1-antitrypsin replacement therapy of the standards committee, Canadian Thoracic Society. CMAJ. 1992;146(6):841–844.1544074
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341. doi:10.1016/j.ijsu.2010.02.00720171303
   PubMed Web of Science ®Google Scholar
• Luisetti M, Seersholm N. Alpha-1- antitrypsin deficiency. 1: epidemiology of alpha-1- antitrypsin deficiency. Thorax. 2004;59(2):164–169. doi:10.1136/thorax.2003.00649414760160
   PubMed Web of Science ®Google Scholar
• de Serres FJ, Blanco I, Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;5:277–295. doi:10.1177/175346581245711322933512
   PubMed Web of Science ®Google Scholar
• Alpha-1 global. Available from: http://alpha-1global.org/en. Accessed 47, 2019.
   Google Scholar
• Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;167(10):1387–1392. doi:10.1164/rccm.200209-1035OC12574076
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi:10.1016/S0140-6736(15)60860-126026936
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Respreeza assessment report. European medicines agency. 2015;1–102. Available from: https://www.ema.europa.eu/en/documents/assessment-report/respreeza-epar-public-assessment-report_en.pdf. Accessed 33, 2019.
   Google Scholar
• FDA. Summary basis for approval OB-NDA 20-0952. Available from: Available from: http://www.fda.gov/CbER/ndasum/hexbio033199S.pdf. Accessed 33, 2019.
   Google Scholar
• Mortensen MB, Nordestgaard BG. Comparison of five major guidelines for statin use in primary prevention in a contemporary general population. Ann Intern Med. 2018;168(2):85–92. doi:10.7326/M17-068129297004
   PubMed Web of Science ®Google Scholar
• Syan R, Brucker BM. Guideline of guidelines: urinary incontinence. BJU Int. 2016;117(1):20–33. doi:10.1111/bju.1318726033093
   PubMed Web of Science ®Google Scholar
• Horner K, O’Malley L, Taylor K, Glenny AM. Guidelines for clinical use of CBCT: a review. Dentomaxillofac Radiol. 2015;44(1):20140225. doi:10.1259/dmfr.2014022525270063
   PubMed Web of Science ®Google Scholar
• Lacasse Y, Ferreira I, Brooks D, Newman T, Goldstein RS. Critical appraisal of clinical practice guidelines targeting chronic obstructive pulmonary disease. Arch Intern Med. 2001;161(1):69–74.11146700
   PubMed Web of Science ®Google Scholar